Abstract:Mantle cell lymphoma (MCL) is a rare type of B-cell-derived non-Hodgkin's lymphoma. In Europe and the United States, the overall incidence of MCL is about 0.5 per 100,000 people, accounting for 2% to 10% of all non-Hodgkin lymphomas. [ 1 ] In recent years, the incidence of MCL has shown an increasing trend, [ 1 ] which may be related to the improvement of diagnostic levels. The male-to-female ratio is 2.3 to 2.5:1, and the median age of diagnosis is about 70 years in Europe and the United States. [ 1 ] The median age of onset of MCL in China was 58 years, accounting for 3.07% of the total lymphoma, [ 2 ] with a male-to-female ratio of about 2:1. [ 2 ] MCL combines the clinical presentation of aggressive lymphoma with the therapeutic response of inert lymphoma and is still a disease with an unmet therapeutic need. Current National Comprehensive Cancer Network guidelines, European Society for Medical Oncology (ESMO) guidelines, and Chinese Society Of Clinical Oncology (CSCO) guidelines, although there is no standard treatment for first-line MCL, have reduced the status of R-cyclophosphamide + aclarubicin + vincristine + prednisone (CHOP) or CHOP-like protocols. In fit patients with age, younger than 65 years old, rituximab in combination with high-dose Ara-C followed by is recommended, followed by 12 courses of rituximab maintenance once every 2 months after completion of treatment, which results in more than 6 years of median survival and a higher 5-year overall survival (OS). [ 3–5 ] For patients older than 65 years old and with non-transplantable initial treatment, bendamustine + rituximab (BR) or rituximab + bendamustine + Ara-C + cyclophosphamide, can be used for early induction therapy to improve patients' progression-free survival (PFS) and improve treatment efficiency. In addition, rituximab maintenance therapy has been shown to significantly prolong PFS in MCL. [ 6 ] Bruton's tyrosine kinase inhibitor (BTKi) is a novel small-molecule targeted drug that has been shown to have excellent efficacy as a single agent in relapsed MCL. The combination of BTKi with other drugs and its application in first-line MCL has also been reported. Ibrutinib treatment in combination with BR significantly prolonged PFS. The median PFS as assessed by the investigators was 80.6 months in the ibrutinib group, as compared with 52.9 months in the placebo group. [ 7 , 8 ] At present, there are few reports about the clinical application of BTKi combined with chemical immunotherapy in patients with initial MCL in China, especially about patients younger than 65 years old, who accepted rituximab combination with high-dose Ara-C. To meet the clinical needs of MCL patients, this study investigated the effect of advancing the use of BTKi in combination with chemotherapy.

Advances in the treatment of mantle cell lymphoma with BTK inhibitors

Novel treatment for mantle cell lymphoma – impact of BTK inhibitors and beyond

Molecular Pathways Associated With Ibrutinib Resistance In Mantle Cell Lymphoma

Clinical and Molecular Biology Analysis of Patients with Mantle Cell Lymphoma Resistant to BTK Inhibitor

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma

Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors

Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia

FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma

BTKi combined with chemical immunotherapy in the initial treatment of aggressive mantle cell lymphoma: A retrospective study

The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View

Harnessing Btki Therapy by CDK4/6i Control of T Effector Memory Cells and T Cell Surveillance in Mantle Cell Lymphoma

Emerging therapies in mantle cell lymphoma

Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies

BTK Inhibitors in CLL: Second Generation Drugs and Beyond

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia

Treatment Patterns and Clinical Outcomes of Mantle Cell Lymphoma: A Retrospective Cohort Study by CHOICE

"The End of the Golden Weather": therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors

Treatment of Relapsed/Refractory MCL

Current approaches and advance in mantle cell lymphoma treatment.